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These are anxious and difficult times in the United States. Rates of 
depression and anxiety have been on the rise due to the COVID-
19 pandemic.1,2 A recent American Psychiatric Association (APA) 
poll indicated that 62% of people feel more anxious than they did 
at this time last year.3 At the very time when anxiety is at a high 
point, our health care system's capacity to address the multiple 
public health issues wrought by the pandemic is under-resourced 
and overwhelmed. Public health agencies such as the U.S. Centers 
for Disease Control and Prevention have been politically hobbled 
and defunded right when they are most needed.4 As a result, the 
long-term physical and mental health of Americans is on the line.  
 
The COVID-19 pandemic has inflamed pre-existing problems 
related to mental health, prescribing practices, and substance use.5 
Pre-existing concerns about prescription drug misuse and the 
surge in availability of tainted, counterfeit drugs have been 
exacerbated by socioeconomic and racial/ethnic inequalities, a 
substandard social safety net, and the mental health burden of the 
pandemic.6   Short-term anti-anxiety medications, also known as 
benzodiazepines, are widely used in the U.S., and while sometimes 
beneficial, they are an area of concern for public health during our 
current mental health crisis. Before the COVID-19 pandemic, 
public health officials and medical experts were already worried 
about the rising rates of prescriptions for benzodiazepines, such as 
Xanax™ (alprazolam).7,8 This concern is supported by CDC data, 
which  shows that the number of fatal overdoses involving 
benzodiazepines increased from 1,135 in 1999 to 10,724 in 
2018.9  
 
In this brief we discuss the implications of benzodiazepine prescribing practices and the challenges of such practices as 
the country emerges from the COVID-19 pandemic. Navigating the risks inherent to benzodiazepines during these 






• Americans are facing significant mental 
health problems, including increased 
anxiety, during the COVID-19 pandemic. 
• Both over-prescribing and under-
prescribing of anti-anxiety drugs carries 
risks. 
• The risks of under-prescribing anti-
anxiety medications include fatal 
withdrawal symptoms or potentially 
pushing individuals to pursue dangerous, 
counterfeit street drugs. The risks of over-
prescribing include addiction and 
dependence. 
• Mental health treatment providers must 
carefully attend to symptom monitoring, 
ongoing therapy, and eventual 
prescription reductions according to risk 
versus benefit during and after the 
pandemic. 
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Pre-Pandemic Concerns about Benzodiazepines 
Pre-pandemic concerns regarding benzodiazepine use generally fell into two categories. The first involves the practice of 
over-prescribing benzodiazepines and the highly addictive properties of this class of drugs.10 Benzodiazepine withdrawal 
can be deadly. Patients taking benzodiazepines for as little as one to six months may experience significant withdrawal 
symptoms that must be medically managed.11,12 The second category of concern involves the supply of contaminated, 
counterfeit pills.14 The highly addictive nature of benzodiazepines like Xanax™ can create situations where people 
sometimes turn to illicit street markets where counterfeit pills are often laced with fentanyl, dramatically increasing the 
risk of overdose.16,17 Fentanyl is a powerful synthetic opioid that is similar to heroin, but much more potent and much 
cheaper. Fentanyl is the leading driver of the increase in drug overdoses in the U.S. over the past several years.9 In light of 
these two issues, maintenance and monitoring of patients prescribed benzodiazepines must be carefully considered.  
 
Concerns about Benzodiazepines during COVID-19 
The concerns described above have been amplified during the COVID-19 pandemic. Anxiety is the most commonly 
diagnosed mental health condition in the U.S., and COVID-19 has exacerbated the country’s existing mental health 
problems. In February, the share of Americans reporting anxiety began to climb, as did benzodiazepine prescriptions. 
From mid-February to mid-March, benzodiazepine prescriptions rose 34.1%. During the week of March 15th alone, 
prescriptions increased by 18%.15 Because of the stay-at-home orders issued in spring of 2020 and physical distancing 
precautions taken by health care providers to reduce risk of coronavirus spread, it became challenging to schedule 
elective appointments, and prescription rates started to decline. According to prescription drug monitoring program 
data from Texas, there were initial reductions in both prescribing and filling of medications from March to June of 
2020.16 Extreme increases and decreases in prescribing carry distinct risks of dependence and overdose. Any decline in 
prescribing by physicians can result in people turning to illicit markets, as we saw with the transition from prescription 
opioids to heroin once states began cracking down on overprescribing and prescription opioids became more difficult to 
get.17 Even when patients are able to see a physician using telehealth and telepsychiatry, they may be at risk of losing 
prescriptions in other ways, including job loss and the subsequent loss of employer-based health insurance.18 Patients 
taking medications that cause dependence without access to legitimate prescriptions may resort to tainted, black market 
drug supplies, as was the case when prescription opioids became more difficult to get from physicians. For example, the 
loss of employer-based health insurance in a state without Medicaid expansion might force an individual who is 
dependent on anxiety medication to seek out such medication on the street, or face withdrawal. The local supply may be 
inundated with fentanyl. Historical epidemiological data suggests this may increase localized overdose rates.19 
 
Caution is Warranted as the Country Emerges from the Pandemic  
There are several steps mental health providers should take over the next couple of months as the U.S. emerges from the 
COVID-19 pandemic. First, medical providers should be alert to the use of benzodiazepines and the mental health 
conditions of their patients. Given the temptation for expedient prescription of short-term solutions in a time of national 
crisis, rising anxiety represents a secondary tide of debilitation that practitioners will have to carefully navigate. 
Rebuilding lives and the economy will create additional sources of anxiety and challenges to physical and mental health. 
Behavioral therapies and carefully monitored anxiety medication must be accessible for the remainder of the pandemic 
and beyond. At the same time, given the danger of addiction, providers must be aware that pushing individuals off 
benzodiazepines may lead to deadly withdrawal or pursuit of street pills, which may be tainted with fentanyl. Managing 
anxiety within the U.S. population will be a persistent challenge as people struggle to rebuild their lives.  Prescribers 
should strongly urge clients to participate in regular telehealth, telepsychiatry, and online counseling. For patients who 
have been prescribed benzodiazepines during the pandemic, providers must carefully weigh symptom monitoring, 
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